Top 10 Research Papers: RAIR Thyroid Cancer (January 21, 2026 Update)

* Study identifies patients who would benefit from redifferentiation therapy for thyroid cancer

https://www.mayoclinic.org/medical-professionals/endocrinology/news/study-identifies-patients-who-would-benefit-from-redifferentiation-therapy-for-thyroid-cancer/mac-20592451

* BRAF and MEK Inhibition Beyond Dabrafenib-Trametinib in Advanced Thyroid Cancer

https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1694805/full

* Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers

https://pubmed.ncbi.nlm.nih.gov/37917101/

* Off-Label Treatment Offers Hope for Patients With Rare Medullary Thyroid Cancer

https://advances.massgeneral.org/oncology/article.aspx?id=1608

* Redifferentiation Effect of Larotrectinib for NTRK Fusion-Positive Pediatric Thyroid Cancer

https://pmc.ncbi.nlm.nih.gov/articles/PMC12209784/

* Pilot Study of BRAF or MEK Inhibition to Restore Iodine Uptake (NCT04554680)

https://clinicaltrials.gov/study/NCT04554680

* Lutathera (177Lu-DOTATATE) Orphans: State of the Art and Future Application of Radioligand Therapy

https://www.researchgate.net/publication/369730901_Lutathera_Orphans_State_of_the_Art_and_Future_Application_of_Radioligand_Therapy_with_Lu-DOTATATE

* Identification of new small molecules for selective inhibition of SERCA 1 in patient-derived metastatic papillary thyroid cancer

https://www.researchgate.net/publication/388836405_Identification_of_new_small_molecules_for_selective_inhibition_of_SERCA_1_in_patient-derived_metastatic_papillary_thyroid_cancer

* Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with RR-DTC

https://www.mdpi.com/2072-6694/13/9/2279

* A TIMELESS link to dedifferentiation in thyroid cancer

https://joe.bioscientifica.com/downloadpdf/view/journals/joe/267/1/JOE-25-0136.pdf